Product Information
VENLAFAXINE HCL ER 150 MG CAP is a generic product labeled by Epic Pharma LLC, priced at $0.1190 per EA under NDC 42806060305. Its NADAC has been published 177 times since May 17, 2023.
FDA first approved this application on Aug 6, 2021. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
150 mg/1
Manufacturer
Epic Pharma LLCNDC
42806060305
Classification
Generic
Dosage Form
CAPSULE, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
VENLAFAXINE HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA214654FDA Approved
8/6/2021
TE Code
AB
On Market Since
9/7/2022
Pharmacological Classes
Price Statistics
The NADAC for VENLAFAXINE HCL ER 150 MG CAP has been published 177 times since May 17, 2023, and over the history we have for it it has declined 21.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1190 per EA |
|---|---|
| All-time high | $0.1568 (Dec 13, 2023) |
| All-time low | $0.1057 (Nov 20, 2024) |
| 52-week high | $0.1309 |
| 52-week low | $0.1152 |
| Median price | $0.1326 |
| Average price | $0.1324 |
| Largest weekly change | +21.6% (Aug 21, 2024) |
| Weeks tracked | 177 |
| Tracking since | May 17, 2023 |
Generic Alternatives
The matcher finds 5 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 2% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Epic Pharma LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
VENLAFAXINE HYDROCHLORIDE market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Serotonin and Norepinephrine Reuptake Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of VENLAFAXINE HCL ER 150 MG CAP?
The current National Average Drug Acquisition Cost (NADAC) for VENLAFAXINE HCL ER 150 MG CAP, manufactured by Epic Pharma LLC, is $0.1190 per EA (NDC 42806060305), effective Sep 30, 2026.
How has the price of VENLAFAXINE HCL ER 150 MG CAP changed over time?
Over the history we have for it, the NADAC for VENLAFAXINE HCL ER 150 MG CAP has declined 21.6%. It has been tracked across 177 weekly CMS publications since May 17, 2023.
What are the highest and lowest recorded NADAC prices for VENLAFAXINE HCL ER 150 MG CAP?
Since May 17, 2023, the NADAC for VENLAFAXINE HCL ER 150 MG CAP has ranged from a low of $0.1057 (Nov 20, 2024) to a high of $0.1568 (Dec 13, 2023), with a median of $0.1326 per EA.
Are there cheaper alternatives to VENLAFAXINE HCL ER 150 MG CAP?
Yes. 5 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, VENLAFAXINE HCL ER 150 MG CAP, is $0.1162 per EA — about 2% below VENLAFAXINE HCL ER 150 MG CAP.
Who manufactures VENLAFAXINE HCL ER 150 MG CAP?
VENLAFAXINE HCL ER 150 MG CAP (NDC 42806060305) is labeled by Epic Pharma LLC, and CMS classifies it as a generic product.